linjc16/ctgov huggingface dataset:
Change in Tongue Strength and Fatigue After Upper Airway Stimulation Therapy

Study Overview
=================
Brief Summary
-----------------
Upper airway stimulation (UAS) is an effective surgical alternative for patients with obstructive sleep apnea (OSA) who fail continuous positive airway pressure (CPAP) therapy. This stimulation could lead to alterations in tongue strength and fatigability which could alter treatment outcome. The aim of the study is to investigate if UAS alters tongue strength and fatigability.

Official Title
-----------------
Change in Tongue Strength and Fatigue After Implantation of Upper Airway Stimulation System

Conditions
-----------------
Obstructive Sleep Apnea of Adult

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old or older upper airway stimulation group: Upper airway stimulation system implanted at least 4 weeks ago OSA group: OSA confirmed by 18-channel inpatient overnight polysomnography (PSG) test group: No medical history for OSA and Epworth Sleepiness Scale (ESS) below 11 Exclusion Criteria: history of a neuromuscular disorder previous tongue surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Upper airway stimulation group<br> | |
| OSA group with conservative / no treatment<br> | |
| Test group without OSA<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tongue protrusion strength | Tongue protrusion strength (peak pressure in kPa) | Up to 60 months after implanation | 
| Tongue fatigability | Time to task failure during 50% of peak pressure contraction in seconds | Up to 60 months after implanation |
Development of Exercise Promotion Program Using a Mobile Community

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the effect of a mobile community based on a smart phone application to enhance physical activities of breast cancer survivors.

Official Title
-----------------
Development of Exercise Promotion Program Using a Mobile Community Based on a Smart Phone Application in Breast Cancer Survivors

Conditions
-----------------
Breast Cancer, Physical Activity

Intervention / Treatment
-----------------
* Device: Mobile community


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage 0-III breast cancer Exclusion Criteria: Stage IV breast cancer Breast cancer recurrence or metastasis Severe medical illness

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: two different single-arm study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mobile Community First<br>Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community. | Device: Mobile community<br>* A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.<br>|
| Experimental: Mobile Community Later<br>Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community. | Device: Mobile community<br>* A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distress | Assessment using Patient Health Questionnaire (PHQ-9) | up to 3months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physical activity | Assessment using International Physical Activity Questionnaire (IPAQ) | up to 3months |
Proteomics of Papillary Thyroid Carcinoma

Study Overview
=================
Brief Summary
-----------------
Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.

Detailed Description
-----------------
Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer. Clinical information, examination data: Information is obtained from medical record abstraction. Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary thyroid carcinoma without cervical lymph node metastasis ).

Official Title
-----------------
Differences Protein Expression in Papillary Thyroid Carcinoma

Conditions
-----------------
Papillary Thyroid Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed papillary thyroid carcinoma. Undergo thyroidectomy according to the China thyroid association guidelines forthe Management of thyroid nodule and thyroid cancer. Exclusion Criteria: Current substance abuse/dependence. Daily tobacco and alcohol use. Whole neck irradiation or surgery. Prior cancer diagnosis or chemotherapy treatment. Active autoimmune disorder. Uncontrolled allergic condition or asthma. Chronic use of oral steroid medication. Hormone therapy (estrogen, progestin compounds).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PTC group 1<br>papillary thyroid carcinoma patients with cervical lymph node metastasis | |
| PTC group 2<br>papillary thyroid carcinoma patients without cervical lymph node metastasis | |
| Positive control group<br>benign disease | |
| Negative control group<br>histologically normal | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| differences in protein expression |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
proteomic, cervical lymph node metastasis
Pharmacology Study of Aerosolized Liposomal

Study Overview
=================
Brief Summary
-----------------
To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization in patients with non-small-cell lung cancer (any stage). To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks, every 10 weeks. To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A specific protocol will be written for this part.

Detailed Description
-----------------
This is a single-arm, non-randomized Phase II trial of DLPC-9NC administered by aerosol 5 consecutive days per week for 8 weeks every 10 weeks. Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks. Patients that have a resectable lung cancer will only receive one course of treatment and will be operated on about two weeks after completing the 8-week course.

Official Title
-----------------
Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S) - Camptothecin (L9NC)

Conditions
-----------------
Cancer, Lung Diseases

Intervention / Treatment
-----------------
* Drug: L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients participating in INST 1402C protocol Phase II Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients with Advanced (NSCLC) Lung Cancer are eligible if their tumor is resectable with curative intent as determined by Dr. Reza Mehran.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathological examination of lung tissure |  | at surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NSCLC, L9NC, Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin
Body Water Content Sensor

Study Overview
=================
Brief Summary
-----------------
Evaluation of hydration status during exercise and heat exposure.

Detailed Description
-----------------
Evaluation of hydration status during exercise and heat exposure.

Official Title
-----------------
Body Water Content Sensor

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: dehydration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-35 Participates in regular exercise Able to tolerate exercise in the heat Exclusion Criteria: Abnormal hemoglobin Any exercise limitations Pregnancy Cardiovascular or orthopedic disease/conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| D,FR<br>Young healthy athletes | Other: dehydration<br>* dehydration to 3% and 5% loss of total body water<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight and hydration status |  | Before exercise and following dehydration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Young healthy athletes
Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration

Study Overview
=================
Brief Summary
-----------------
The purpose of this collaboration is to establish a multi-modality image database including coronary angiograms, optical coherence tomography (OCT), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. The main goal of this collaboration is to create a resource to promote further understanding of the pathobiology of atherosclerosis through image analysis.

Detailed Description
-----------------
The purpose of this collaboration is to establish a multi-modality image database including coronary angiograms, optical coherence tomography (OCT), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. About one thousand patients who underwent coronary angiography with OCT and had a CTA prior to catheterization at Tsuchiura Kyodo General Hospital (TKGH) in Japan, will be included. A subset of these patients also had CMR. The main goal of this collaboration is to create a resource to promote further understanding of the pathobiology of atherosclerosis through image analysis.

Official Title
-----------------
Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration

Conditions
-----------------
Atherosclerosis

Intervention / Treatment
-----------------
* Other: Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Had CTA prior to cardiac catheterization and then OCT during catheterization Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute Coronary Syndrome<br>Patients diagnosed with acute coronary syndrome. | Other: Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)<br>* Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.<br>|
| Stable Angina<br>Patients diagnosed with stable angina. | Other: Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)<br>* Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major Adverse Cardiac Events (MACE) | MACE | 1 Year |
Multidisciplinary Team in Management of Placenta Accreta

Study Overview
=================
Brief Summary
-----------------
comparative study between the incidence of urological injury in case of placenta accreta in cases where urological surgical staff are participating in the operation from the start and in cases where the operation is carried by the gynecological staff only

Detailed Description
-----------------
cohort of 1000 patients of placenta accreta are followed regarding the incidence of urological injury in the cases with assistance from the urological staff members

Official Title
-----------------
is There Any Superior Benefit of Multidisciplinary Team in Management of Placenta Accreta

Conditions
-----------------
Placenta Accreta

Intervention / Treatment
-----------------
* Procedure: cesarean section or cesarean hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant 38 weeks placenta accreta Exclusion Criteria: medical disorders complicating pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| multidisciplinary team group<br>500 patients of placenta accreta managed by obstetricans and urologists | Procedure: cesarean section or cesarean hysterectomy<br>* upper segment cesarean section and or cesarean hysteroctomy<br>|
| obstetricians only group<br>500 patients of placenta accreta managed by obstetricans only | Procedure: cesarean section or cesarean hysterectomy<br>* upper segment cesarean section and or cesarean hysteroctomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urological injury | badder or ureteric injury | intraoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
placenta accreta
Effects of Weight Loss in Obese Difficult-to-treat Asthmatics

Study Overview
=================
Brief Summary
-----------------
Sixty percent of patients with difficult to control asthma seen in our outpatient clinic are obese. The impact of weight reduction in this subpopulation of asthmatics has not been studied. Our aim is to evaluate the impact of weight reduction on asthma control of these patients.

Detailed Description
-----------------
Study design: interventional, open label, randomized Patients selection Thirty-three difficult to control obese asthmatic patients, aged between 18 to 65 years old will be recruited from the outpatient clinics of the Pulmonary Division of the University of Sao Paulo Hospital. Difficult to control asthma will be defined as patients who do not achieve asthma control (according to GINA) despite best treatment regimen and checked adherence after at least three months of treatment. Intervention: Patients will be divided in two groups: asthma treatment plus weight loss program or asthma treatment alone for 6 months without drug dose changing. Procedures (baseline and after 6 months) - quality of life questionnaire, asthma control questionnaire, lung function tests, serum and sputum inflammatory markers.

Official Title
-----------------
Effects of Weight Loss in Obese Difficult-to-treat Asthmatics: a Pilot Study

Conditions
-----------------
Asthma, Obesity, Weight Loss

Intervention / Treatment
-----------------
* Behavioral: Low caloric diet plus orlistat and sibutramine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Difficult-to-treat asthma Body mass index > 30kg/m2 Exclusion Criteria: Subjets older than 65 years Current smoking Past smoking history (> 10 pack-year) Pregnancy Contraindication for Orlistat or Sibutramine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: weight loss<br> | Behavioral: Low caloric diet plus orlistat and sibutramine<br>* All subjetcs<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma control questionnaire (ACQ) |  | Baseline and six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory parameters |  | Baseline and after 6 months | 
| Pulmonary mechanics |  | Baseline and after 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Obesity, weight loss
Accuracy of CVC Depth Prediction in Internal Jugular Veins: The Difference Between The Andropoulos and ECG Methods

Study Overview
=================
Brief Summary
-----------------
compare the accuracy of CVC depth prediction in internal jugular veins: the difference between the andropoulos and ECG methods

Detailed Description
-----------------
seventy two subjects were given informed consent before the study started. compare the accuracy of CVC depth prediction in internal jugular veins with two difference methods, the andropoulos method and ECG method.

Official Title
-----------------
Accuracy of CVC Depth Prediction in Internal Jugular Veins: The Difference Between The Andropoulos and ECG Methods

Conditions
-----------------
Depth of CVC Insertion

Intervention / Treatment
-----------------
* Other: andropulous method
* Device: ECG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signing informed consent form indicated for CVC insertion has no contraindication for right internal jugular vein CVC insertion Exclusion Criteria: has history of arrhythmia has cardiac malformation history
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Andropulous method<br>Andropulous method uses equations to determine the depth of CVC insertion. For subject with <100 cm in height: Depth of CVC insertion (cm) = (height (cm)/ 10)-1 For subject with >100 cm in height: Depth of CVC insertion (cm) = (height (cm)/ 10)-2 | Other: andropulous method<br>* Counts the CVC depth using specific equation<br>|
| Active Comparator: ECG method<br>change in p wave from ECG | Device: ECG<br>* Using ECG to monitor the insertion of the CVC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CVC prediction depth using andropulous equation | CVC will be inserted in certain depth according to the calculated depth | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ECG change | changes in p wave during CVC insertion | 30 seconds |